Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on November 8, 2022. The filing announces the release of earnings results for the third quarter ended October 1, 2022. The company's ordinary shares and various notes are registered on the New York Stock Exchange.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release and defines the methodology for non-GAAP financial measures rather than reporting the figures themselves.
The company utilizes the following non-GAAP measures to evaluate performance:
- Adjusted gross profit and margin
- Adjusted operating income and margin
- Adjusted net income and diluted earnings per share (including constant currency)
- Constant currency net sales growth
- Organic net sales growth
Material Changes and Adjustments
The filing details specific items excluded from non-GAAP measures to facilitate period-to-period comparability. These adjustments differ between the current and prior periods:
Three Months Ended October 1, 2022 Adjustments:
- Acquisition and integration-related charges and contingent consideration adjustments
- Amortization expense related to acquired intangible assets
- Restructuring charges and termination benefits
- Loss on early debt extinguishment
- Unusual litigation
- (Gain) loss on divestitures and investment securities
- Non-GAAP tax adjustments and foreign currency translation movement
Three Months Ended October 2, 2021 Adjustments:
- Impairment charges
- Amortization expense related to acquired intangible assets
- Unusual litigation
- Restructuring charges and termination benefits
- Acquisition and integration-related charges
- (Gain) loss on divestitures
- Net SPA arbitration settlement award
- Non-GAAP tax adjustments and foreign currency translation movement
Guidance, Outlook, and Risks
Management uses these adjusted financial measures for planning, forecasting, and determining compensation. The filing emphasizes that non-GAAP measures should be considered in conjunction with, not as a substitute for, GAAP financial statements. No specific forward-looking guidance or new risk factors are detailed in this text; the primary focus is on the definition of financial metrics used in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, earnings, and cash flow figures.
- Verify the specific dollar amounts of the "Loss on early debt extinguishment" and "Unusual litigation" cited as adjustments for the current quarter.
- Compare the current quarter's non-GAAP adjustments against the prior year's "Net SPA arbitration settlement award" and "Impairment charges" to understand volatility drivers.
- Confirm the reconciliation between GAAP and non-GAAP net income and earnings per share in the full earnings release.